Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of ...
The Company's results for 2024 are characterized by: A net loss of €9.3m in 2024, compared to a loss of €21.2m in 2023, mainly due to: By way of comparison, 2023 revenue of €2.2m included revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results